

Philip S Helliwell

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/4385667/publications.pdf](https://exaly.com/author-pdf/4385667/publications.pdf)

Version: 2024-02-01

241
papers

13,384
citations

43617

47
h-index

25840

106
g-index

271
all docs

271
docs citations

271
times ranked

8380
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. <i>Arthritis and Rheumatism</i> , 2006, 54, 2665-2673. | 6.9 | 2,909 |
| 2 | Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1060-1071. | 6.7 | 767 |
| 3 | Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17. | 7.8 | 513 |
| 4 | Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 6-16. | 7.8 | 401 |
| 5 | Evaluation of a novel 7â€œjoint ultrasound score in daily rheumatologic practice: A pilot project. <i>Arthritis and Rheumatism</i> , 2009, 61, 1194-1201. | 6.9 | 381 |
| 6 | Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2008, 59, 686-691. | 6.9 | 361 |
| 7 | A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1012-1019. | 7.8 | 332 |
| 8 | The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 986-991. | 7.8 | 250 |
| 9 | Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNFÎ± inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1115-1125. | 12.1 | 232 |
| 10 | A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 123-131. | 7.8 | 221 |
| 11 | Psoriatic arthritis: state of the art review. <i>Clinical Medicine</i> , 2017, 17, 65-70. | 1.9 | 218 |
| 12 | Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. <i>Arthritis Care and Research</i> , 2010, 62, 965-969. | 3.7 | 207 |
| 13 | Development of a preliminary composite disease activity index in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 272-277. | 7.8 | 190 |
| 14 | Assessment of patients with psoriatic arthritis: A review of currently available measures. <i>Arthritis and Rheumatism</i> , 2004, 50, 24-35. | 6.9 | 173 |
| 15 | Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial. <i>Arthritis and Rheumatology</i> , 2019, 71, 1112-1124. | 6.7 | 172 |
| 16 | Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2018, 392, 2367-2377. | 12.1 | 170 |
| 17 | Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. <i>Nature Communications</i> , 2015, 6, 6046. | 13.0 | 159 |
| 18 | Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. <i>Rheumatology and Therapy</i> , 2016, 3, 91-102. | 2.5 | 159 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 291-304. | 3.5 | 127 |
| 20 | Phosphodiesterase 4 Inhibition in the Treatment of Psoriasis, Psoriatic Arthritis and Other Chronic Inflammatory Diseases. <i>Dermatology and Therapy</i> , 2013, 3, 1-15. | 3.2 | 108 |
| 21 | The impact of rheumatoid arthritis on foot function in the early stages of disease: a clinical case series. <i>BMC Musculoskeletal Disorders</i> , 2006, 7, 102. | 1.9 | 106 |
| 22 | Patient Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA and OMERACT Study. <i>Journal of Rheumatology</i> , 2011, 38, 898-903. | 2.1 | 105 |
| 23 | International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1235-1242. | 6.9 | 104 |
| 24 | Development of a foot impact scale for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005, 53, 418-422. | 6.9 | 103 |
| 25 | Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study. <i>Journal of Rheumatology</i> , 2016, 43, 356-361. | 2.1 | 92 |
| 26 | Tofacitinib for the treatment of psoriasis and psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 719-730. | 3.1 | 92 |
| 27 | Functional and work outcomes improve in patients with rheumatoid arthritis who receive targeted, comprehensive occupational therapy. <i>Arthritis and Rheumatism</i> , 2009, 61, 1522-1530. | 6.9 | 91 |
| 28 | The TICOPA protocol (Tight Control of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. <i>BMC Musculoskeletal Disorders</i> , 2013, 14, 101. | 1.9 | 91 |
| 29 | A comparison of the performance characteristics of classification criteria for the diagnosis of psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 34, 575-584. | 3.5 | 90 |
| 30 | Defining Low Disease Activity States in Psoriatic Arthritis using Novel Composite Disease Instruments. <i>Journal of Rheumatology</i> , 2016, 43, 371-375. | 2.1 | 88 |
| 31 | Sensitivity and specificity of the Classification of Psoriatic Arthritis criteria in early psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 3150-3155. | 6.9 | 85 |
| 32 | Is There Subclinical Synovitis in Early Psoriatic Arthritis? A Clinical Comparison With Grayâ€šScale and Power Doppler Ultrasound. <i>Arthritis Care and Research</i> , 2014, 66, 432-439. | 3.7 | 79 |
| 33 | Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensusâ€šBased Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 345-355. | 6.7 | 78 |
| 34 | Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1759-1766. | 3.7 | 74 |
| 35 | Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placeboâ€šControlled Study. <i>Arthritis Care and Research</i> , 2016, 68, 267-274. | 3.7 | 69 |
| 36 | Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study. <i>Rheumatology</i> , 2015, 54, 157-162. | 2.1 | 68 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1882-1885. | 7.8 | 65 |
| 38 | Brief Report: Reduced Joint Counts Misclassify Patients With Oligoarticular Psoriatic Arthritis and Miss Significant Numbers of Patients With Active Disease. <i>Arthritis and Rheumatism</i> , 2013, 65, 1504-1509. | 6.9 | 62 |
| 39 | Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. <i>Lancet Rheumatology</i> , The, 2021, 3, e715-e723. | 4.1 | 60 |
| 40 | Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 649-655. | 1.2 | 59 |
| 41 | Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 358-362. | 7.8 | 57 |
| 42 | Comparison of Composite Measures of Disease Activity in Psoriatic Arthritis Using Data From an Interventional Study With Golimumab. <i>Arthritis Care and Research</i> , 2014, 66, 749-756. | 3.7 | 57 |
| 43 | Creativity in 21st-century education. <i>Prospects</i> , 2014, 44, 575-589. | 2.4 | 56 |
| 44 | Drug Therapies for Peripheral Joint Disease in Psoriatic Arthritis: A Systematic Review. <i>Journal of Rheumatology</i> , 2014, 41, 2277-2285. | 2.1 | 52 |
| 45 | A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 654-665. | 3.5 | 51 |
| 46 | Fatigue in psoriatic arthritis—A cross-sectional study of 246 patients from 13 countries. <i>Joint Bone Spine</i> , 2016, 83, 439-443. | 1.8 | 50 |
| 47 | Psoriatic Arthritis Spondylitis Radiology Index: A Modified Index for Radiologic Assessment of Axial Involvement in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 1006-1011. | 2.1 | 49 |
| 48 | Pathophysiology, assessment and treatment of psoriatic dactylitis. <i>Nature Reviews Rheumatology</i> , 2019, 15, 113-122. | 8.1 | 49 |
| 49 | Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFi inhibitor-experienced. <i>RMD Open</i> , 2021, 7, e001457. | 4.3 | 48 |
| 50 | Comprehensive Treatment of Dactylitis in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2295-2300. | 2.1 | 47 |
| 51 | Assessing Disease Activity in Psoriatic Arthritis: A Literature Review. <i>Rheumatology and Therapy</i> , 2019, 6, 23-32. | 2.5 | 47 |
| 52 | Foot orthoses in the treatment of symptomatic midfoot osteoarthritis using clinical and biomechanical outcomes: a randomised feasibility study. <i>Clinical Rheumatology</i> , 2016, 35, 987-996. | 2.3 | 46 |
| 53 | The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA-B*27 Status?. <i>Arthritis Care and Research</i> , 2021, 73, 856-860. | 3.7 | 46 |
| 54 | Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials. <i>RMD Open</i> , 2020, 6, e001149. | 4.3 | 40 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Treating to target in psoriatic arthritis: how to implement in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 640-643. | 7.8 | 39 |
| 56 | Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110579. | 2.8 | 39 |
| 57 | Classification of the spondyloarthropathies. <i>Current Opinion in Rheumatology</i> , 2005, 17, 395-399. | 4.4 | 38 |
| 58 | Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis. <i>Rheumatology and Therapy</i> , 2015, 2, 1-16. | 2.5 | 38 |
| 59 | Development of a Disease Severity and Responder Index for Psoriatic Arthritis (PsA) – Report of the OMERACT 10 PsA Special Interest Group. <i>Journal of Rheumatology</i> , 2011, 38, 1496-1501. | 2.1 | 37 |
| 60 | Patient global assessment in psoriatic arthritis – what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. <i>Joint Bone Spine</i> , 2016, 83, 335-340. | 1.8 | 37 |
| 61 | Enhanced Patient Involvement and the Need to Revise the Core Set – Report from the Psoriatic Arthritis Working Group at OMERACT 2014. <i>Journal of Rheumatology</i> , 2015, 42, 2198-2203. | 2.1 | 36 |
| 62 | Patient Involvement in Outcome Measures for Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2014, 16, 418. | 4.9 | 35 |
| 63 | Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). <i>Rheumatology</i> , 2020, 59, 2774-2784. | 2.1 | 35 |
| 64 | Development of Screening Tools to Identify Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2010, 12, 295-299. | 4.9 | 34 |
| 65 | Debridement of painful forefoot plantar callosities in rheumatoid arthritis: the CARROT randomised controlled trial. <i>Clinical Rheumatology</i> , 2013, 32, 567-574. | 2.3 | 34 |
| 66 | Involvement of superoxide dismutase in oxidative stress in the oriental fruit fly, <i>Bactrocera dorsalis</i> : molecular cloning and expression profiles. <i>Pest Management Science</i> , 2013, 69, 1315-1325. | 3.6 | 34 |
| 67 | Development of a Disease Activity and Responder Index for Psoriatic Arthritis – Report of the Psoriatic Arthritis Module at OMERACT 11. <i>Journal of Rheumatology</i> , 2014, 41, 782-791. | 2.1 | 34 |
| 68 | It's not just the joints, it's the whole thing: qualitative analysis of patients' experience of flare in psoriatic arthritis. <i>Rheumatology</i> , 2015, 54, 1448-1453. | 2.1 | 33 |
| 69 | Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. <i>RMD Open</i> , 2022, 8, e002074. | 4.3 | 33 |
| 70 | Psoriasis Epidemiology Screening Tool (PEST): A Report from the GRAPPA 2009 Annual Meeting. <i>Journal of Rheumatology</i> , 2011, 38, 551-552. | 2.1 | 32 |
| 71 | Disease measurement – enthesitis, skin, nails, spine and dactylitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010, 24, 659-670. | 3.5 | 31 |
| 72 | Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort. <i>Arthritis Care and Research</i> , 2018, 70, 1198-1205. | 3.7 | 31 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Current concepts and unmet needs in psoriatic arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 297-305. | 2.3 | 30 |
| 74 | Dactylitis: Pathogenesis and clinical considerations. <i>Current Rheumatology Reports</i> , 2006, 8, 338-341. | 4.9 | 27 |
| 75 | Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. <i>RMD Open</i> , 2021, 7, e001486. | 4.3 | 27 |
| 76 | What Should Be the Primary Target of "Treat to Target" in Psoriatic Arthritis?. <i>Journal of Rheumatology</i> , 2019, 46, 38-42. | 2.1 | 26 |
| 77 | Axial disease in psoriatic arthritis. <i>Rheumatology</i> , 2020, 59, 1193-1195. | 2.1 | 26 |
| 78 | Development of Criteria to Distinguish Inflammatory from Noninflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , 2014, 41, 1249-1251. | 2.1 | 25 |
| 79 | Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 965-969. | 2.1 | 25 |
| 80 | Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients' health-related quality of life and productivity. <i>BMC Rheumatology</i> , 2018, 2, 24. | 1.7 | 25 |
| 81 | Modification of the Psoriatic Arthritis Disease Activity Score (PASDAS). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 467-468. | 7.8 | 24 |
| 82 | Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. <i>Arthritis Research and Therapy</i> , 2018, 20, 242. | 3.6 | 24 |
| 83 | Cardiovascular Diseases in Psoriasis and Psoriatic Arthritis. <i>Journal of rheumatology Supplement</i> , The, 2019, 95, 20-27. | 2.5 | 24 |
| 84 | Relationship of psoriatic arthritis with the other spondyloarthropathies. <i>Current Opinion in Rheumatology</i> , 2004, 16, 344-349. | 4.4 | 23 |
| 85 | Composite Measures in Psoriatic Arthritis: A Report from the GRAPPA 2009 Annual Meeting. <i>Journal of Rheumatology</i> , 2011, 38, 540-545. | 2.1 | 23 |
| 86 | Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study. <i>RMD Open</i> , 2020, 6, e001217. | 4.3 | 23 |
| 87 | Use of conservative and surgical foot care in an inception cohort of patients with rheumatoid arthritis. <i>Rheumatology</i> , 2011, 50, 1586-1595. | 2.1 | 22 |
| 88 | Development and Testing of New Candidate Psoriatic Arthritis Screening Questionnaires Combining Optimal Questions From Existing Tools. <i>Arthritis Care and Research</i> , 2014, 66, 1410-1416. | 3.7 | 22 |
| 89 | Clinical Examination, Ultrasound and MRI Imaging of The Painful Elbow in Psoriatic Arthritis and Rheumatoid Arthritis: Which is Better, Ultrasound or MR, for Imaging Enthesitis?. <i>Rheumatology and Therapy</i> , 2017, 4, 71-84. | 2.5 | 22 |
| 90 | The Diagnosis and Treatment of Adult Patients with SAPHO Syndrome: Controversies Revealed in a Multidisciplinary International Survey of Physicians. <i>Rheumatology and Therapy</i> , 2020, 7, 883-891. | 2.5 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 91 | Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1815-1823. | 2.1 | 21 |
| 92 | Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling. <i>Arthritis and Rheumatology</i> , 2022, 74, 1535-1543. | 6.7 | 21 |
| 93 | Development of diagnostic criteria for psoriatic arthritis: Methods and process. <i>Current Rheumatology Reports</i> , 2004, 6, 299-305. | 4.9 | 20 |
| 94 | The predictors of foot ulceration in patients with rheumatoid arthritis: a preliminary investigation. <i>Clinical Rheumatology</i> , 2008, 27, 1423-1428. | 2.3 | 20 |
| 95 | A case series to describe the clinical characteristics of foot ulceration in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2012, 31, 541-545. | 2.3 | 20 |
| 96 | A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis | | |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 109 | The predictors of foot ulceration in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2014, 33, 615-621. | 2.3 | 17 |
| 110 | The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome. <i>Rheumatology</i> , 2016, 55, 2277-2278. | 2.1 | 17 |
| 111 | Treat to Target in Psoriatic Arthritis—Evidence, Target, Research Agenda. <i>Current Rheumatology Reports</i> , 2015, 17, 517. | 4.9 | 16 |
| 112 | Limitations in the Classification of Childhood-onset Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 547-553. | 2.1 | 15 |
| 113 | Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a multicentre, open-label, randomised controlled trial. <i>Lancet</i> , The, 2014, 383, S36. | 12.1 | 15 |
| 114 | Sensitivity and Specificity of Radiographic Scoring Instruments for Detecting Change in Axial Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2017, 69, 1700-1705. | 3.7 | 15 |
| 115 | Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naïve early psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 490-495. | 7.8 | 15 |
| 116 | Magnetic Resonance Arthrography of Lesser Metatarsophalangeal Joints in Patients with Rheumatoid Arthritis: Relationship to Clinical, Biomechanical, and Radiographic Variables. <i>Journal of Rheumatology</i> , 2012, 39, 1786-1791. | 2.1 | 14 |
| 117 | Focussing on the foot in psoriatic arthritis: pathology and management options. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 21-28. | 3.1 | 14 |
| 118 | Efficacy and Safety of the <sc>TYK2</sc>/<sc>JAK1</sc> Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase <sc>IIb</sc> Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2023, 75, 1370-1380. | 6.7 | 14 |
| 119 | Remission in Psoriatic Arthritis. <i>Journal of rheumatology Supplement</i> , The, 2012, 89, 19-21. | 2.5 | 13 |
| 120 | Development of a Flare Instrument for Use in Psoriatic Disease: A Report from the 2015 GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 974-978. | 2.1 | 13 |
| 121 | Radiographic Progression in Psoriatic Arthritis Achieving a Good Response to Treatment: Data Using Newer Composite Indices of Disease Activity. <i>Arthritis Care and Research</i> , 2018, 70, 797-800. | 3.7 | 13 |
| 122 | Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial. <i>Arthritis Care and Research</i> , 2020, 72, 1579-1588. | 3.7 | 13 |
| 123 | Comparing Psoriatic Arthritis Low-field Magnetic Resonance Imaging, Ultrasound, and Clinical Outcomes: Data from the TICOPA Trial. <i>Journal of Rheumatology</i> , 2020, 47, 1338-1343. | 2.1 | 13 |
| 124 | Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. <i>Rheumatology</i> , 2021, 60, 1137-1147. | 2.1 | 13 |
| 125 | Classification and categorisation of psoriatic arthritis. <i>Clinical Rheumatology</i> , 2008, 27, 1211-1216. | 2.3 | 12 |
| 126 | Assessment of Enthesitis in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 869-870. | 2.1 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | The definition of remission in psoriatic arthritis: can this be accurate without assessment of multiple domains?. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e66-e66. | 7.8 | 11 |
| 128 | Physicianâ€™s Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study. <i>Journal of Rheumatology</i> , 2018, 45, 1256-1262. | 2.1 | 11 |
| 129 | Patient Reported Outcomes in Chronic Inflammatory Diseases: Current State, Limitations and Perspectives. <i>Frontiers in Immunology</i> , 2021, 12, 614653. | 4.8 | 11 |
| 130 | The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. <i>Rheumatology</i> , 2022, 61, e255-e266. | 2.1 | 11 |
| 131 | Long-term follow-up of patients in the Tight COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial. <i>Rheumatology</i> , 2020, 59, 807-810. | 2.1 | 10 |
| 132 | Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib. <i>Arthritis Research and Therapy</i> , 2021, 23, 94. | 3.6 | 10 |
| 133 | Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study. <i>Journal of Rheumatology</i> , 2021, , jrheum.201674. | 2.1 | 10 |
| 134 | Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trial. <i>Lancet Rheumatology</i> , The, 2022, 4, e252-e261. | 4.1 | 10 |
| 135 | Screening psoriatic arthritis tools: analysis of the Early Arthritis for Psoriatic Patients questionnaire. <i>Rheumatology</i> , 2015, 54, 200-202. | 2.1 | 9 |
| 136 | A discrete choice experiment to explore patientsâ€™ willingness to risk disease relapse from treatment withdrawal in psoriatic arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 2967-2974. | 2.3 | 9 |
| 137 | Replication of a distinct psoriatic arthritis risk variant at the L23R locus. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1417-1418. | 7.8 | 9 |
| 138 | The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 303. | 1.9 | 9 |
| 139 | Plantar plate pathology is associated with erosive disease in the painful forefoot of patients with rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 308. | 1.9 | 9 |
| 140 | GRAPPA Responder Index Project (GRACE): A Report from the GRAPPA 2011 Annual Meeting. <i>Journal of Rheumatology</i> , 2012, 39, 2196-2197. | 2.1 | 8 |
| 141 | Prologue: 2016 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Journal of Rheumatology</i> , 2017, 44, 658-660. | 2.1 | 8 |
| 142 | Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies. <i>ACR Open Rheumatology</i> , 2020, 2, 543-554. | 2.0 | 8 |
| 143 | Updates on Axial Psoriatic Arthritis From the 2020 GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2021, , jrheum.201672. | 2.1 | 8 |
| 144 | Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. <i>Rheumatology</i> , 2023, 62, 606-616. | 2.1 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 145 | Psoriasis and Psoriatic Arthritis Educational Initiatives: An Update from the 2013 GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2014, 41, 1240-1243. | 2.1 | 7 |
| 146 | Systematic Exploration of the High Likelihood Set of Phylogenetic Tree Topologies. <i>Systematic Biology</i> , 2020, 69, 280-293. | 5.9 | 7 |
| 147 | Moving Toward Precision Medicine in Psoriasis and Psoriatic Arthritis. <i>Journal of rheumatology Supplement, The</i> , 2020, 96, 19-24. | 2.5 | 7 |
| 148 | Best-practice Indicators in Psoriatic Disease Care. <i>Journal of rheumatology Supplement, The</i> , 2019, 95, 38-45. | 2.5 | 7 |
| 149 | GRAPPA 2018 Project Report. <i>Journal of rheumatology Supplement, The</i> , 2019, 95, 54-57. | 2.5 | 7 |
| 150 | GRAPPA 2019 Project Report. <i>Journal of rheumatology Supplement, The</i> , 2020, 96, 53-57. | 2.5 | 7 |
| 151 | Agreement Between Internal Astigmatism and Posterior Corneal Astigmatism in Pseudophakic Eyes. <i>Journal of Refractive Surgery</i> , 2018, 34, 379-386. | 2.3 | 6 |
| 152 | Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA). <i>Trials</i> , 2020, 21, 155. | 1.6 | 6 |
| 153 | A clinical and radiographic comparison of patients with psoriatic arthritis from different ethnic backgrounds. <i>Rheumatology</i> , 2021, 60, 340-345. | 2.1 | 6 |
| 154 | Comparing the Visual Analog Scale and the Numerical Rating Scale in Patient-reported Outcomes in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 836-840. | 2.1 | 6 |
| 155 | Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo. <i>Arthritis Research and Therapy</i> , 2022, 24, 40. | 3.6 | 6 |
| 156 | Treat-to-target in psoriatic arthritis is "cost-effective in the biosimilar era. <i>Lancet Rheumatology, The</i> , 2022, 4, e390-e391. | 4.1 | 6 |
| 157 | Management of Dactylitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. <i>Journal of Rheumatology</i> , 2023, 50, 265-278. | 2.1 | 6 |
| 158 | GRAPPA 2013 Annual Meeting, Rheumatology Updates: Psoriatic Arthritis (PsA) Biomarker Project, Arthritis Mutilans, PsA-Peripheral Spondyloarthritis Epidemiology Project. <i>Journal of Rheumatology</i> , 2014, 41, 1244-1248. | 2.1 | 5 |
| 159 | Diurnal variation of gait in patients with rheumatoid arthritis: The DIVIGN study. <i>Clinical Biomechanics</i> , 2014, 29, 811-814. | 1.3 | 5 |
| 160 | Interleukin-17 inhibition in psoriatic arthritis. <i>Lancet, The</i> , 2015, 386, 1114-1116. | 12.1 | 5 |
| 161 | Interpreting outcome following foot surgery in people with rheumatoid arthritis. <i>Journal of Foot and Ankle Research</i> , 2016, 9, 20. | 2.0 | 5 |
| 162 | Prologue: 2015 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Journal of Rheumatology</i> , 2016, 43, 949-951. | 2.1 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | To Lump or Split When Assessing Psoriatic Arthritis " Not Mutually Exclusive?. Journal of Rheumatology, 2020, 47, 307-309. | 2.1 | 5 |
| 164 | Evaluation and Validation of a Patient-completed Psoriatic Arthritis Flare Questionnaire. Journal of Rheumatology, 2021, 48, 1268-1271. | 2.1 | 5 |
| 165 | Composite Measures for Routine Clinical Practice in Psoriatic Arthritis: Testing of Shortened Versions in a UK Multicenter Study. Journal of Rheumatology, 2021, , jrheum.201675. | 2.1 | 5 |
| 166 | Tacrolimus in Patients With Interstitial Pneumonia Associated With Polymyositis or Dermatomyositis: Interim Report of Postmarketing Surveillance in Japan. Journal of Rheumatology, 2022, 49, 707-718. | 2.1 | 5 |
| 167 | Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study. Patient, 2022, 15, 657-668. | 2.9 | 5 |
| 168 | Comment on: Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology, 2010, 49, 1793-1794. | 2.1 | 4 |
| 169 | Joint Orthopaedic and Rheumatology Clinics: Evidence to Support the Guidelines. Musculoskeletal Care, 2011, 9, 180-183. | 1.6 | 4 |
| 170 | Radiography Versus Magnetic Resonance Imaging (MRI) in Juvenile Spondyloarthritis: Is the MR Image Everything?. Journal of Rheumatology, 2014, 41, 832-833. | 2.1 | 4 |
| 171 | Screening for Psoriatic Arthritis in People with Psoriasis. Journal of Rheumatology, 2015, 42, 736-738. | 2.1 | 4 |
| 172 | Systematic literature review of non-topical treatments for early, untreated (systemic therapy naïve) psoriatic disease: a GRAPPA initiative. Rheumatology Advances in Practice, 2020, 4, rkaa032. | 0.7 | 4 |
| 173 | On the question of labor productivity. Scientific Bulletins of the Belgorod State University Series Economics Computer Science, 2018, 45, 268-272. | 0.0 | 4 |
| 174 | Safety of tetrahydrocurcuminoids from turmeric (<i>Curcuma longa</i> L.) as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal, 2021, 19, e06936. | 1.8 | 4 |
| 175 | Correspondence on "No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related "physician-reported spondylitis"â€™. Annals of the Rheumatic Diseases, 2023, 82, e187-e187. | 7.8 | 4 |
| 176 | Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial. RMD Open, 2022, 8, e002366. | 4.3 | 4 |
| 177 | Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, <sc>Placeboâ€Controlled DISCOVER</sc>â€ Study. ACR Open Rheumatology, 2023, 5, 149-164. | 2.0 | 4 |
| 178 | Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group. Journal of Rheumatology, 2023, 50, 53-57. | 2.1 | 4 |
| 179 | Human nocturnal blood melatonin and liver acetylation status. Journal of Pineal Research, 1991, 10, 14-17. | 7.6 | 3 |
| 180 | The Role of Auditing in the Management of Corporate Fraud. Developments in Corporate Governance and Responsibility, 2014, , 129-151. | 0.0 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | GRAPPA 2015 Research and Education Project Reports. <i>Journal of Rheumatology</i> , 2016, 43, 979-985. | 2.1 | 3 |
| 182 | Verna Wright: father of the spondyloarthropathies. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 454-455. | 7.8 | 3 |
| 183 | Pustular Psoriasis and Associated Musculoskeletal Disorders. <i>Journal of Rheumatology</i> , 2021, , jrheum.201673. | 2.1 | 3 |
| 184 | The BSR-PsA: study protocol for the British Society for Rheumatology psoriatic arthritis register. <i>BMC Rheumatology</i> , 2021, 5, 19. | 1.7 | 3 |
| 185 | Prologue: 2017 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Journal of rheumatology Supplement, The</i> , 2018, 94, 1-3. | 2.5 | 3 |
| 186 | Molecular and cellular regulation of psoriatic inflammation. <i>Clinical Science</i> , 2022, 136, 935-952. | 4.3 | 3 |
| 187 | Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis. <i>RMD Open</i> , 2022, 8, e002457. | 4.3 | 3 |
| 188 | Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis: Comment on the article by Clegg et al. <i>Arthritis and Rheumatism</i> , 1997, 40, 1911-1912. | 6.9 | 2 |
| 189 | The Art and Science of Tapering Glucocorticoids in Patients with Rheumatic Diseases. <i>Journal of Rheumatology</i> , 2014, 41, 1252.1-1252. | 2.1 | 2 |
| 190 | Presidential Round Table: A Report from the GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 986-989. | 2.1 | 2 |
| 191 | GRAPPA 2016 Project Report. <i>Journal of Rheumatology</i> , 2017, 44, 706-710. | 2.1 | 2 |
| 192 | Werner syndrome: a rare cause of osteoporosis in a young female. <i>Rheumatology</i> , 2018, 57, 2021-2021. | 2.1 | 2 |
| 193 | Measuring Physical Function in Psoriatic Arthritis: Comparing the Multidimensional Health Assessment Questionnaire to the Health Assessment Questionnaire's Disability Index. <i>Journal of Rheumatology</i> , 2021, 48, 1686-1691. | 2.1 | 2 |
| 194 | Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC. <i>Rheumatology</i> , 2022, 62, e1-e3. | 2.1 | 2 |
| 195 | Screening and Referral Strategies for the Early Recognition of Psoriatic Arthritis Among Patients With Psoriasis: Results of a GRAPPA Survey. <i>Journal of Rheumatology</i> , 2023, 50, 1439-1445. | 2.1 | 2 |
| 196 | An international multicentre analysis of current prescribing practices and shared decision-making in psoriatic arthritis. <i>Rheumatology</i> , 0, , . | 2.1 | 2 |
| 197 | How do patient-reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients. <i>Rheumatology</i> , 0, , . | 2.1 | 2 |
| 198 | Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study. <i>RMD Open</i> , 2024, 10, e003977. | 4.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Practical Applications of Risk Parity, Maximum Diversification, and Minimum Variance: An Analytic Perspective. <i>Practical Applications</i> , 2014, 1, 1.6-4. | 0.0 | 1 |
| 200 | Aiming for remission in psoriatic arthritis. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 147-153. | 0.3 | 1 |
| 201 | The NICE appraisal of ustekinumab for treating psoriatic arthritis. <i>British Journal of Health Care Management</i> , 2016, 22, 68-71. | 0.4 | 1 |
| 202 | An educational leaflet improves response to invitation for screening for arthritis in patients with psoriasis in primary care, but only in practices in the most deprived areas. <i>Clinical Rheumatology</i> , 2017, 36, 719-723. | 2.3 | 1 |
| 203 | Evaluating the cost-effectiveness of biologic treatments for psoriatic arthritis: can we make better use of patient data registries?. <i>Clinical Rheumatology</i> , 2017, 36, 1803-1810. | 2.3 | 1 |
| 204 | AB0742â€¦. ACHIEVEMENT OF PASDAS LOW DISEASE ACTIVITY AND VERY LOW DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL OVER 4 YEARS AND THE OVERLAP WITH DAPSA AND MDA DISEASE ACTIVITY TARGETS. <i>Annals of the Rheumatic Diseases</i> , 2019, , . | 7.8 | 1 |
| 205 | P262â€¦ Guselkumab, an anti-interleukin-23p19 monoclonal antibody, in patients with active PsA who were biologic-naïve or prior TNFÎ± inhibitor-treated: week 24 results of a Phase 3, randomised, double-blind, placebo-controlled study. <i>Rheumatology</i> , 2020, 59, . | 2.1 | 1 |
| 206 | P174â€¦ Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC. <i>Rheumatology</i> , 2021, 60, . | 2.1 | 1 |
| 207 | 4. Morfosintaxis diacrÃ³nica. , 2019, , 96-132. | | 1 |
| 208 | Processing and Added Value of Bamboo in Tasikmalaya, West Java. <i>Jurnal Wasian</i> , 2020, 7, 51-63. | 0.2 | 1 |
| 209 | Clinical trajectories of hand function impairment in systemic sclerosis: an unmet clinical need across disease subsets. <i>RMD Open</i> , 2024, 10, e003216. | 4.3 | 1 |
| 210 | High prevalence of radiographic erosions in early, untreated PsA: results from the SpARRO cohort. <i>RMD Open</i> , 2024, 10, e003841. | 4.3 | 1 |
| 211 | Biomechanics of the foot in rheumatoid arthritis: Identifying abnormal function and the factors that predict disease impact. <i>Clinical Biomechanics</i> , 2008, 23, 719-720. | 1.3 | 0 |
| 212 | The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite Disease Index Project (GRACE). <i>Psoriasis Forum</i> , 2011, 17a, 216-219. | 0.1 | 0 |
| 213 | Quality Care: Where We Came From and Where We Must Go. <i>Clinical Journal of Oncology Nursing</i> , 2013, 17, 236-238. | 0.6 | 0 |
| 214 | I58.â€¦ Therapy of PSA: What is New and How Can We Treat to Target?. <i>Rheumatology</i> , 2014, 53, i13-i13. | 2.1 | 0 |
| 215 | 177.â€¦ Mechanical Factors that May Contribute to Toe Dactylitis in Patients with Psoriatic Arthritis. <i>Rheumatology</i> , 2014, 53, i125-i126. | 2.1 | 0 |
| 216 | 179.â€¦ Foot Orthoses in the Treatment of Symptomatic Midfoot Osteoarthritis Using Clinical and Biomechanical Outcomes: A Feasibility Study. <i>Rheumatology</i> , 2014, 53, i126-i126. | 2.1 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | I58â€fPsoriatic Arthritis: Anti-Tumour Necrosis Factor and Beyond. <i>Rheumatology</i> , 0, , . | 2.1 | 0 |
| 218 | I111â€fStrategies for the Use of Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis, Including Treat to Target. <i>Rheumatology</i> , 0, , . | 2.1 | 0 |
| 219 | L.C. Coates and P.S. Helliwell reply. <i>Journal of Rheumatology</i> , 2016, 43, 1766.2-1766. | 2.1 | 0 |
| 220 | La fatigue dans le rhumatisme psoriasique. Ã‰tude transversale portant sur 246Âpatients de 13Âpays. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017, 84, 321-325. | 0.0 | 0 |
| 221 | Que signifie lâ€™Ã©valuation globale par le patient dans le rhumatisme psoriasique? Une analyse de 223Âpatients issus de lâ€™Ã©tude dâ€™Ã©laboration du Psoriatic Arthritis Impact of Disease (PsAID). <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017, 84, 314-320. | 0.0 | 0 |
| 222 | O69.â€fCONSTRUCT VALIDITY, RESPONSIVENESS AND MINIMALLY IMPORTANT DIFFERENCE OF THE ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3 IN PSORIATIC ARTHRITIS. <i>Rheumatology</i> , 2017, 56, . | 2.1 | 0 |
| 223 | A new era for collaboration?. <i>Rheumatology</i> , 2018, 57, 775-776. | 2.1 | 0 |
| 224 | AB0745â€f...ASSESSMENT OF DISEASE ACTIVITY USING RAPID3 AND EVALUATION OF TREATMENT EFFECT OF GUSELKUMAB IN PATIENTS WITH PSA: RESULTS FROM A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL. <i>Annals of the Rheumatic Diseases</i> , 2019, , . | 7.8 | 0 |
| 225 | SAT0387â€f...CONSISTENT EFFICACY IN PATIENT SUBGROUPS ACROSS BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS: RESULTS FROM A PHASE 2 STUDY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2019, , . | 7.8 | 0 |
| 226 | BSR Spondyloarthritis Course, 27 February 2020. Spondyloarthritis: pathogenesis, diagnosis and management. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa043. | 0.7 | 0 |
| 227 | P277â€fAssessment of disease activity using RAPID3 and evaluation of treatment effect of guselkumab in patients with PsA: results from a randomised placebo-controlled Phase 2 clinical trial. <i>Rheumatology</i> , 2020, 59, . | 2.1 | 0 |
| 228 | Photography as a Reflection of the Photographerâ€™s Pain in Time Stands Still. <i>Arab World English Journal for Translation and Literary Studies</i> , 2021, 5, 99-112. | 0.1 | 0 |
| 229 | Ãœber die Autoren. , 2021, , 207-210. | | 0 |
| 230 | GRAPPA 2020 Update From the Education Committee. <i>Journal of Rheumatology</i> , 2021, , jrheum.201678. | 2.1 | 0 |
| 231 | P172â€fQuality of life improvements in patients with PsA who achieve remission or low disease activity targets: results from two clinical trials of ixekizumab at three years of treatment. <i>Rheumatology</i> , 2021, 60, . | 2.1 | 0 |
| 232 | Development of an Instrument for Patient Self-assessment in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, jrheum.210010. | 2.1 | 0 |
| 233 | Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores. <i>Clinical Trials</i> , 2021, 18, 541-551. | 1.8 | 0 |
| 234 | The comparative performance of three screening questionnaires for psoriatic arthritis in a primary care surveillance study. <i>Rheumatology</i> , 2024, 63, 991-998. | 2.1 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 235 | Elevating the Standard of Care for Patients with Psoriatic Arthritis: â€˜Calls to Actionâ€™™ from a Multistakeholder Pan-European Initiative. <i>Rheumatology and Therapy</i> , 2024, 11, 795-815. | 2.5 | 0 |
| 236 | The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Celebrates Its 20th Anniversary. <i>Journal of Rheumatology</i> , 0, , jrheum.2024-0230. | 2.1 | 0 |
| 237 | GRAPPA 2023: Major Projects, Key Advances, and Milestones. <i>Journal of Rheumatology</i> , 0, , jrheum.2024-0266. | 2.1 | 0 |
| 238 | High prevalence of undiagnosed and undertreated psoriasis in a UK urban population: results from the observational COPPACA study. <i>British Journal of Dermatology</i> , 0, , . | 1.7 | 0 |
| 239 | Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis, Palmoplantar Pustulosis, and Neutrophilic Dermatoses: A GRAPPA 2023 Annual Meeting Update. <i>Journal of Rheumatology</i> , 0, , jrheum.2024-0592. | 2.1 | 0 |
| 240 | The development and validation of a novel training infographic for the Physician Visual Analogue Scale (VAS) in Psoriatic Arthritis.. <i>Journal of Rheumatology</i> , 0, , jrheum.2024-0152. | 2.1 | 0 |
| 241 | Incidence of psoriatic arthritis in a UK primary care psoriasis population. <i>Journal of Rheumatology</i> , 0, , jrheum.2024-0556. | 2.1 | 0 |